Literature DB >> 25125257

CHK it out! Blocking WEE kinase routs TP53 mutant cancer.

Julie E Bauman1, Christine H Chung2.   

Abstract

Mutations in TP53, encoding the master tumor suppressor p53, have posed a developmental therapeutic dilemma due to inability to target loss of function. Inhibition of WEE1 or CHK1 kinase, negative regulators of the G2-M checkpoint, selectively sensitizes p53-deficient cells to exogenous DNA damage, abrogating G2 arrest and precipitating mitotic catastrophe. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25125257      PMCID： PMC4860818          DOI： 10.1158/1078-0432.CCR-14-0720

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Authors:  Y Wang; J Li; R N Booher; A Kraker; T Lawrence; W R Leopold; Y Sun
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.

Authors:  Hiroshi Hirai; Yoshikazu Iwasawa; Megumu Okada; Tsuyoshi Arai; Toshihide Nishibata; Makiko Kobayashi; Toshifumi Kimura; Naoki Kaneko; Junko Ohtani; Kazunori Yamanaka; Hiraku Itadani; Ikuko Takahashi-Suzuki; Kazuhiro Fukasawa; Hiroko Oki; Tadahiro Nambu; Jian Jiang; Takumi Sakai; Hiroharu Arakawa; Toshihiro Sakamoto; Takeshi Sagara; Takashi Yoshizumi; Shinji Mizuarai; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

3.  Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Authors:  Russell Moser; Chang Xu; Michael Kao; James Annis; Luisa Angelica Lerma; Christopher M Schaupp; Kay E Gurley; In Sock Jang; Asel Biktasova; Wendell G Yarbrough; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez
Journal:  Clin Cancer Res       Date:  2014-08-15       Impact factor: 12.531

4.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Authors:  Edward Sausville; Patricia Lorusso; Michael Carducci; Judith Carter; Mary F Quinn; Lisa Malburg; Nilofer Azad; David Cosgrove; Richard Knight; Peter Barker; Sonya Zabludoff; Felix Agbo; Patricia Oakes; Adrian Senderowicz
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-22       Impact factor: 3.333

5.  The mutational landscape of head and neck squamous cell carcinoma.

Authors:  Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Authors:  Kathleen A Bridges; Hiroshi Hirai; Carolyn A Buser; Colin Brooks; Huifeng Liu; Thomas A Buchholz; Jessica M Molkentine; Kathryn A Mason; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2011-07-28       Impact factor: 12.531

7.  Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.

Authors:  Daisuke Sano; Tong-Xin Xie; Thomas J Ow; Mei Zhao; Curtis R Pickering; Ge Zhou; Vlad C Sandulache; David A Wheeler; Richard A Gibbs; Carlos Caulin; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2011-09-08       Impact factor: 12.531

8.  TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Authors:  Heath D Skinner; Vlad C Sandulache; Thomas J Ow; Raymond E Meyn; John S Yordy; Beth M Beadle; Alison L Fitzgerald; Uma Giri; K Kian Ang; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

9.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Authors:  M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

Review 10.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824
View more
  11 in total

Review 1.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

2.  Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

Authors:  C H Chung; V B Guthrie; D L Masica; C Tokheim; H Kang; J Richmon; N Agrawal; C Fakhry; H Quon; R M Subramaniam; Z Zuo; T Seiwert; Z R Chalmers; G M Frampton; S M Ali; R Yelensky; P J Stephens; V A Miller; R Karchin; J A Bishop
Journal:  Ann Oncol       Date:  2015-02-23       Impact factor: 32.976

Review 3.  The genomics and epigenetics of olfactory neuroblastoma: A systematic review.

Authors:  Raman Preet Kaur; Evgeny Izumchenko; Dukagjin M Blakaj; Nikol Mladkova; Matt Lechner; Thomas L Beaumont; Charalampos S Floudas; Gary L Gallia; Nyall R London
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-06-07

4.  A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.

Authors:  Anne Margriet Heijink; Vincent A Blomen; Xavier Bisteau; Fabian Degener; Felipe Yu Matsushita; Philipp Kaldis; Floris Foijer; Marcel A T M van Vugt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

5.  Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.

Authors:  Jasmina Topcagic; Rebecca Feldman; Anatole Ghazalpour; Jeffrey Swensen; Zoran Gatalica; Semir Vranic
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

6.  Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Authors:  Rossanna C Pezo; Tom W Chen; Hal K Berman; Anna M Mulligan; Albiruni A Razak; Lillian L Siu; David W Cescon; Eitan Amir; Christine Elser; David G Warr; Srikala S Sridhar; Celeste Yu; Lisa Wang; Tracy L Stockley; Suzanne Kamel-Reid; Philippe L Bedard
Journal:  Breast Cancer Res Treat       Date:  2017-11-24       Impact factor: 4.872

7.  Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.

Authors:  Dongshao Chen; Xiaoting Lin; Jing Gao; Lin Shen; Zhongwu Li; Bin Dong; Cheng Zhang; Xiaotian Zhang
Journal:  Biomed Res Int       Date:  2018-06-07       Impact factor: 3.411

8.  Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors.

Authors:  Yassi Fallah; Diane M Demas; Lu Jin; Wei He; Ayesha N Shajahan-Haq
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Authors:  Kathleen A Bridges; Xingxing Chen; Huifeng Liu; Crosby Rock; Thomas A Buchholz; Stuart D Shumway; Heath D Skinner; Raymond E Meyn
Journal:  Oncotarget       Date:  2016-11-01

Review 10.  A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

Authors:  Andrea Ghelli Luserna di Rorà; Claudio Cerchione; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2020-09-21       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.